What Determines Who Develops Type 1 Diabetes After Autoantibodies Appear?

Type 1 diabetes doesn't develop overnight. It follows a recognizable sequence: the immune system first produces autoantibodies—proteins that mistakenly target the insulin-producing cells in the pancreas. For months or years, people can carry these autoantibodies without showing symptoms or changes in blood sugar. Eventually, blood sugar begins to rise, and eventually clinical Type 1 diabetes appears.

Most research on this progression has come from families with a genetic predisposition to Type 1 diabetes—a relatively narrow group. A new study looked at what happens in the broader, real-world population, examining nearly 7,000 people who tested positive for diabetes-related autoantibodies but had not yet developed Type 1 diabetes.

The study's most striking finding: children progress to Type 1 diabetes much faster than adults. Children with a single autoantibody were 4 times more likely to develop Type 1 diabetes within three years compared to adults. Children with two or more autoantibodies faced an even steeper risk—approximately 7 times higher than adults.

This age difference held true whether blood sugar remained normal or entered the prediabetic range. The biological reasons for this acceleration in children remain an active area of research, but the pattern is clear and consistent.

Beyond age, two other factors shaped progression risk: how many autoantibodies a person carried, and whether their blood sugar had begun to rise. Among people with only one autoantibody, a modest increase in blood sugar (from the normal range into the prediabetic range) roughly doubled or tripled progression risk. In children with one autoantibody and normal blood sugar, the risk increased by 44 percent with higher blood sugar. In adults, the same increase in blood sugar raised risk nearly threefold.

Interestingly, in people who already had two or more autoantibodies, blood sugar levels made less difference. Their risk was already elevated regardless of glucose levels.

This study reinforces what doctors and researchers have long suspected: progression from autoimmunity to Type 1 diabetes is not one-size-fits-all. Risk depends on a combination of factors working together—how old someone is, how many autoantibodies they've developed, and whether blood sugar is already beginning to drift upward.

For patients and families identified with autoantibodies, understanding these risk factors may help guide conversations with healthcare providers about monitoring and future options for prevention research, such as clinical trials of immune-modifying therapies.

Source: Diabetic medicine : a journal of the British Diabetic Association. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.